Charles River Laboratories International (CRL) Non-Current Deffered Revenue (2010 - 2011)
Charles River Laboratories International (CRL) posted Non-Current Deffered Revenue of $25.4 million for Q3 2011, up 1.05% on a QoQ basis from $25.2 million in Q2 2011.
Powered by 
Analysis
Charles River Laboratories International (CRL) Non-Current Deffered Revenue (2010 - 2011) Analysis & Trends
Charles River Laboratories International has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $25.4 million in Q3 2011.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $25.4 million in Q3 2011; TTM through Sep 2011 was $25.4 million, a N/A change from a year earlier, with the FY2010 full-year figure at $24.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was $25.4 million for Q3 2011 at Charles River Laboratories International, up from $25.2 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $25.4 million in Q3 2011, with the low at $24.7 million in Q4 2010.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | - |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | - |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | - |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | - |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | - |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | 158.90 Mn |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 76.54 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | - |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | - |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 24, 2011 | 25.45 Mn |
| Jun 25, 2011 | 25.18 Mn |
| Dec 25, 2010 | 24.66 Mn |